CARDIOVASCULAR JOURNAL OF AFRICA • Vol 21, No 2, March/April 2010
96
AFRICA
Chen CH, Nakayama M, Nevo E, Fetics BJ, Maughan WL, Kass DA.
6.
Coupled systolic-ventricular and vascular stiffening with age: implica-
tions for pressure regulation and cardiac reserve in the elderly.
J Am Coll
Cardiol
1998;
32
: 1221–1227.
Berne RM, Levy MN. Peripheral circulation and its control.
7.
Physiology
,
4th edn. Sydney: Mosby, 1998, Vol. 1: 1130.
World Health Organization. Second Report of the Expert Committee on
8.
Diabetes. Geneva. World Health Org, 1980; (Tech Rep Ser 646).
Bruce RA. Exercise testing of patients with coronary disease. Principles
9.
and normal standards for evaluation.
Ann Clin Res
1971;
3
: 323–332.
Devereux RB, Liebson PR, Horan MJ. Recommendations concern-
10.
ing use of echocardiography in hypertension and general population
research.
Hypertension
1987;
9
(Suppl II): 97–104.
Sahn DJ, DeMaria A, Kisslo J. Recommendations regarding quantitation
11.
in M-mode electrocardiography: results of a survey of echocardiograph-
ic measurements.
Circulation
1978;
58
: 1072–1083.
Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli
12.
WP. Echocardiographic criteria for left ventricular hypertrophy: the
Framingham Heart Study.
Am J Cardiol
1987;
59
: 956–960.
Reichek M, Devereux RB. Reliable estimation of peak left ventricular
13.
systolic pressure by M-mode echocardiographic determined end-diastol-
ic relative wall thickness. Identification of severe valvular aortic stenosis
in adult patients.
Am Heart J
1982;
103
: 202–209.
Iwashima Y, Horio T, Kuroda S, Takishita S, Kawano Y. Influence of
14.
plasma aldosterone on left ventricular geometry and diastolic function in
treated essential hypertension.
Hypertens Res
2002;
25
: 49–56.
Chaturvedi N, McKeigue PM, Marmot MG. Resting and ambula-
15.
tory blood pressure differences in Afro-Caribbeans and Europeans.
Hypertension
1993;
22
: 90–96.
Marfella R, Nappo F, De Angelis L, Paolisso G, Tagliamonte MR,
16.
Giugliano D. Hemodynamic effects of acute hyperglycemia in type 2
diabetic patients.
Diabetes Care
2000;
23
: 658–663.
Beltran A, McVeigh G, Morgan D,
17.
et al.
Arterial compliance abnor-
malities in isolated systolic hypertension.
Am J Hypertens
2001;
14
:
1007–1011.
Kizu A, Koyama H, Tanaka S, Maeno T, Komatsu M, Fukumoto S,
18.
et al
.
Arterial wall stiffness is associated with peripheral circulation in patients
with type 2 diabetes.
Atherosclerosis
2003;
170
: 87–91.
Balogun MO, Eniola A. Exercise induced ventricular arrhythmias in
19.
Nigerian patients with hypertension.
Trop Cardiol
1995;
21
: 53–58.
Okura H, Inoue H, Tomon M, Nishiyama S, Yoshikawa T, Yoshida K,
20.
et al
. Impact of Doppler-derived left ventricular diastolic performance
on exercise capacity in normal individuals.
Am Heart J
2000;
139
:
716–722.
Boehringer Ingelheim launches Care foundation and get-together
of its sponsored medical students
Boehringer Ingelheim launched its collec-
tive Corporate Social Investment (CSI)
initiatives under one umbrella, the Care
foundation, at a special function in Cape
Town recently.
Consisting of a number of initiatives,
including the provision of anti-retrovirals
free of charge for use in the prevention of
mother-to-child transmission of HIV, HIV
education programmes, and a fully spon-
sored programme for medical students
from disadvantaged backgrounds, the
Care Foundation will have the support
of patrons Prof Rolf Krebs, former chair-
man of the Board of Managing Directors,
Boehringer Ingelheim GmBH, and
Mr Paul Stewart, previously CEO of
Boehringer Ingelheim South Africa and
now corporate senior vice-president, PM/
CHC Emerging Markets, Boehringer
Ingelheim GmBH.
Prof Rolf Krebs pointed out that
education and leadership are key to South
African and African ambitions. ‘This
programme with its already-qualified 22
students can provide leadership in health
policy and delivery that is so essential to
improving the lives of South Africans. We
have to be the leaders’, he warned. Eighty
per cent of these medical students spon-
sored by Boehringer Ingelheim are still
practicing in South Africa.
To date, Boehringer Ingelheim has
invested R6.4 million in the programme,
which includes sponsorship of academic
and residence fees for the seven-year
study period. In line with its ongoing
vision to add value to the lives of its
patients, its people and its communities,
the company has committed to continue
the programme indefinitely and ensure
that there will be 12 students participating
in the programme at all times.
Dirk van Niekerk, country chairman
of Boehringer Ingelheim South Africa,
commented: ‘Doctors and pharmacists
are the lifeblood of the health industry.
At the forefront of improving the lives
of their patients, they play a crucial role
in the communities they serve – and yet,
up to 1994, there were few or no doctors
from previously disadvantaged communi-
ties in South Africa, as a result of political
barriers, inadequate secondary education
and poverty.’
From left to right: Sheldon Marais (current student), Dirk van Niekerk (country
chairman, Boehringer Ingelheim, SA), Siphesihle Khwela (current student),
Prof Rolf Krebs (patron of the Boehringer Ingelheim Care foundation),
Mlekeleli Gumbu (current student).
